Clinical Trials
755 trialsNCT05765084 2026-06-05
Immuno-MESODEC
University Hospital, Antwerp
Phase 1/2 Recruiting
NCT06233942 2026-06-05
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06554795 2026-06-05
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT06710756 2026-06-05
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT06885697 2026-06-05
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06894745 2026-06-05
PET [89Zr]DFO-starPEG in Solid Tumors
University of California, San Francisco
Phase 1 Recruiting
NCT07205718 2026-06-05
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Takeda
Phase 1/2 Recruiting
NCT07223125 2026-06-05
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07359820 2026-06-05
ReFocus202
Elevar Therapeutics
Phase 2 Recruiting
NCT06480552 2026-06-04
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT06596473 2026-06-04
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06756035 2026-06-04
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT07362888 2026-06-04
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Adcendo ApS
Phase 1 Recruiting
NCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT05981703 2026-06-03
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06589596 2026-06-03
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07042100 2026-06-03
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
Phase 1 Recruiting
NCT07077434 2026-06-03
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07226349 2026-06-03
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07414836 2026-06-03
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06031441 2026-06-02
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06126276 2026-06-02
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06815575 2026-06-02
A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.
Racura Oncology Ltd
Phase 1 Recruiting
NCT07387068 2026-06-02
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT07584226 2026-06-02
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
Phase 1 Recruiting
NCT06619587 2026-06-01
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06833008 2026-06-01
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT07196644 2026-06-01
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
AbbVie
Phase 2 Recruiting
NCT07524348 2026-06-01
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Samsung Bioepis Co., Ltd.
Phase 1 Recruiting
NCT07612189 2026-06-01
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
NEOK Bio, Inc.
Phase 1 Recruiting
NCT06246955 2026-05-29
Acceptance and Commitment Therapy and Compassion-Based Virtual Group Therapy to Improve Psychological Wellbeing in Patients With Cancer
Mayo Clinic
Phase NA Recruiting
NCT06598800 2026-05-29
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06625593 2026-05-29
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07141407 2026-05-29
Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person
Fred Hutchinson Cancer Center
Phase NA Recruiting
NCT07480733 2026-05-29
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT04855656 2026-05-28
MYTHIC
Debiopharm International SA
Phase 1 Recruiting
NCT06167317 2026-05-28
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT06477419 2026-05-28
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06541158 2026-05-28
TRACT
Emory University
Phase NA Recruiting
NCT06723041 2026-05-28
Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy
Mayo Clinic
Phase NA Recruiting
NCT06922357 2026-05-28
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT07469774 2026-05-28
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Recruiting
NCT07538479 2026-05-28
NIVALIS
West China Hospital
Phase 1 Recruiting
NCT07541534 2026-05-28
A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Recruiting
NCT07591155 2026-05-28
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05599048 2026-05-27
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
University of California, San Francisco
Phase 1/2 Recruiting
NCT06248411 2026-05-27
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Recruiting
NCT07095868 2026-05-27
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Everest Medicines (China) Co.,Ltd.
Phase 1/2 Recruiting
NCT07228247 2026-05-27
A Phase â… /â…¡a Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Hutchmed
Phase 1/2 Recruiting
NCT07407504 2026-05-27
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting